A comprehensive guide to the six FDA-approved botulinum toxin products for treating glabellar lines (frown lines), including efficacy, safety, and how to choose the right option.
Last reviewed: 2026-05-06
12 min read
Ready to explore your options in Istanbul?
Connect with our coordination team for a personalised treatment plan, verified provider matching, and travel logistics support.
Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
Six FDA-approved botulinum toxin products exist for glabellar lines, but they are NOT interchangeable—dosing varies significantly by product.
Efficacy rates range from approximately 67-80% responder rates at peak effect, with duration typically spanning 3-6 months depending on the product.
Complication rates average around 16% of injection sessions, with eyelid ptosis occurring in 1-5% of treatments (technique-dependent).
Provider experience significantly impacts outcomes—verify credentials and experience with glabellar line treatments specifically.
Results vary between individuals—duration, degree of response, and optimal dosing require personalized assessment.
Educational information only
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
Understanding Glabellar Lines
Glabellar lines—commonly called "frown lines" or "11 lines"—are the vertical wrinkles that form between the eyebrows. These lines develop from repeated contraction of the corrugator supercilii, procerus, and orbicularis oculi muscles over time. When these muscles contract during expressions like concentration, anger, or squinting, they pull the skin into creases that, with repeated movement and factors like sun exposure and skin aging, may become permanently visible even at rest.
The distinction between dynamic and static lines matters for treatment considerations. Dynamic lines appear only during muscle contraction, while static lines remain visible when the face is at rest. Botulinum toxin type A injections work by temporarily relaxing the underlying muscles, which may reduce the appearance of dynamic lines and, with repeated treatment, can also help prevent the deepening of static lines.
For foundational information on how botulinum toxin works, review our Botox Injectables Hub.
When treatment may be appropriate
Glabellar line treatment with botulinum toxin is FDA-approved for adults. The decision to pursue treatment depends on individual factors including the depth of lines, personal preferences, and medical history. A qualified provider can assess whether treatment may be suitable during an in-person consultation.
FDA-Approved Botulinum Toxin Options
Six botulinum toxin products have received FDA approval specifically for treating glabellar lines in the United States. Each product has unique characteristics regarding formulation, dosing, diffusion, and duration of effect. Understanding these differences supports more informed discussions with healthcare providers. The injectables treatments overview provides additional context on botulinum toxin options.
Feature
Product
Generic Name
FDA Approval
Typical Dose (Female)
Duration (Typical)
Botox Cosmetic
Botox Cosmetic
OnabotulinumtoxinA
2002
20 units
3-4 months
Dysport
Dysport
AbobotulinumtoxinA
2009
50 units
3-4 months
Xeomin
Xeomin
IncobotulinumtoxinA
2010
20 units
3-4 months
Jeuveau
Jeuveau
PrabotulinumtoxinA
2019
20 units
3-4 months
Daxxify
Daxxify
DaxibotulinumtoxinA
2022
40 units
5-6 months
Letybo
Letybo
LetibotulinumtoxinA
2023
20 units
3-4 months
Botox Cosmetic (OnabotulinumtoxinA)
Botox Cosmetic, approved by the FDA in 2002, was the first botulinum toxin product approved for cosmetic use in treating glabellar lines. Clinical data from FDA registration trials involving 537 subjects demonstrated approximately 80% responder rates at peak effect (around day 30) [S1]. Effects typically last 3-4 months, though individual response may vary based on factors such as metabolism, muscle strength, and injection technique.
The prescribing information approved by the FDA provides specific dosing guidelines that providers follow when administering treatment [S2]. Botox Cosmetic contains complexing proteins, which distinguishes it from some newer formulations.
Dysport (AbobotulinumtoxinA)
Dysport received FDA approval in 2009 for glabellar line treatment. This formulation has a different unit definition compared to Botox Cosmetic—approximately 3 units of Dysport are considered equivalent to 1 unit of Botox for treatment planning purposes [S3]. The typical female dose is 50 units.
Clinical studies suggest Dysport may have a slightly faster onset of action (2-5 days) compared to Botox (7-14 days) [S4]. Diffusion characteristics also differ, which may influence provider selection for specific anatomical considerations.
Xeomin (IncobotulinumtoxinA)
Xeomin, approved in 2010, is notable for its protein-free formulation—it contains only the active neurotoxin without complexing proteins [S5]. This characteristic may be relevant for patients concerned about protein exposure or those who have developed antibodies to other formulations.
Clinical data demonstrates comparable efficacy to other botulinum toxin products for glabellar line treatment [S6]. The typical dose matches Botox Cosmetic at 20 units for female patients.
Jeuveau (PrabotulinumtoxinA)
Jeuveau received FDA approval in 2019 and is marketed as a "newtox" option. Phase III FDA registration trials demonstrated 67-70% responder rates compared to 1% for placebo [S7]. The typical dose is 20 units for glabellar line treatment.
This product was developed specifically for aesthetic use, distinguishing it from some other formulations that were initially approved for therapeutic applications before receiving cosmetic approval.
Daxxify (DaxibotulinumtoxinA)
Daxxify, approved in 2022, represents the newest advancement in botulinum toxin technology. Its distinguishing feature is a novel peptide excipient that may provide extended duration of effect—up to 6 months in some patients [S8].
Importantly, Daxxify uses a different dosing standard: 40 units for typical female glabellar line treatment (equivalent to the 20-unit dose of other products). This higher unit count reflects the formulation's potency and different unit definition.
Letybo (LetibotulinumtoxinA)
Letybo received FDA approval in 2023, making it the most recently approved botulinum toxin for glabellar lines. Clinical trials demonstrated efficacy comparable to existing approved products [S6]. The typical dose is 20 units, matching Botox Cosmetic, Xeomin, and Jeuveau.
Why Products Are Not Interchangeable
A critical consideration for patients is that these six products, while all FDA-approved for the same indication, are not interchangeable. Several factors contribute to this distinction.
Unit conversion is not straightforward
Each product has its own unit definition established through clinical trials. Converting between products requires understanding that 1 unit of Botox does not equal 1 unit of Dysport or Daxxify. Providers use specific conversion ratios based on clinical evidence, and patients should not assume equivalent dosing across products.
Unit Definitions and Dosing: The unit measurements for botulinum toxin products are product-specific and based on individual manufacturer testing. Botox Cosmetic, Xeomin, Jeuveau, and Letybo use a 20-unit female dose for glabellar lines, while Dysport uses 50 units and Daxxify uses 40 units—not because they deliver more or less of the active ingredient, but because the unit definition differs for each formulation [S2].
Diffusion Characteristics: Products differ in how they spread in tissue after injection. Some have tighter diffusion (remaining more localized), while others diffuse more widely. This characteristic can be advantageous or disadvantageous depending on the treatment goals and anatomical considerations. Providers consider diffusion patterns when selecting products for specific outcomes [S4].
Formulation Excipients: Each product contains different inactive ingredients that affect stability, storage requirements, and potential allergenicity. Xeomin's protein-free formulation, for example, may be relevant for patients with specific concerns about protein exposure.
Evidence-Based Efficacy
Clinical trial data provides insight into expected outcomes, though individual response can vary significantly.
Clinical research demonstrates that botulinum toxin treatment for glabellar lines produces measurable improvement in the majority of appropriately selected patients. FDA registration trials for the various products established efficacy through standardized assessment scales, with responder rates ranging from approximately 67% to 80% at peak effect compared to placebo response rates of 1-3% [S1].
Several factors can influence individual response to treatment. Sex differences affect dosing requirements—male patients typically require higher doses (40-80 units depending on product) due to greater muscle mass in the treatment area. Previous treatment history may influence response, though neutralizing antibody formation with current formulations is rare (less than 1%). Metabolism, activity level, and anatomical variations in muscle patterns can all affect duration and degree of response [S9].
Results cannot be guaranteed
Individual response to botulinum toxin treatment varies based on numerous factors including anatomy, metabolism, muscle strength, previous exposure, and injection technique. While clinical trials demonstrate efficacy in appropriately selected populations, your individual results may differ from trial averages.
Safety Profile and Risks
Understanding the safety profile supports informed decision-making. Botulinum toxin injections for glabellar lines have been studied extensively since FDA approval began in 2002.
A systematic review of 24 studies comprising 4,268 injection sessions found an overall complication rate of approximately 16% of injection sessions [S10]. Most complications are temporary and resolve without intervention.
Common side effects occurring in clinical trials included headache, bruising at injection sites, and mild injection-related reactions. These typically resolve within days to weeks. More technique-dependent complications include eyelid ptosis (drooping), which occurred in 1-5% of treatments and is related to injection placement and product diffusion. Brow asymmetry and dry eye have also been reported less frequently.
For additional safety considerations specific to glabellar line treatment, consult our provider credentials and facility resources.
Contraindications requiring disclosure
Certain conditions may make botulinum toxin treatment unsuitable. These include neuromuscular disorders (such as myasthenia gravis or Lambert-Eaton syndrome), active infection at the injection site, pregnancy or breastfeeding, allergy to any product ingredients, and certain medications that may interact with botulinum toxin. Disclose your complete medical history and all medications during consultation.
Products like Botox Cosmetic, Dysport, and Xeomin carry specific warnings in their FDA-approved labeling regarding potential spread of toxin effects beyond the injection site, though this is rare with appropriate dosing and technique [S2].
Choosing a Qualified Provider
Provider selection significantly impacts treatment outcomes. Botulinum toxin administration requires detailed understanding of facial anatomy, injection technique, and product-specific considerations.
When evaluating providers, verify appropriate credentials and licensing for your jurisdiction. The American Board of Cosmetic Surgery and similar organizations provide guidelines for safe injection practices [S9]. Experience specifically with glabellar line injections matters—a provider who regularly performs these treatments may achieve more consistent results and lower complication rates.
What to look for in a provider
Appropriate medical licensure and credentials specific to your jurisdiction
Training and certification in facial anatomy and botulinum toxin injection
Experience with the specific products discussed during consultation
Willingness to answer questions and discuss treatment goals
Documentation practices for product tracking and follow-up care
For guidance on verifying provider credentials, see our provider credentials resource.
For international patients considering treatment in Istanbul, facility accreditation, provider credentials, and clear communication about product identification and sourcing are important considerations. Request documentation of the specific product used for your medical records.
Treatment Planning
Effective treatment planning considers timing, maintenance needs, and documentation for ongoing care.
Initial results typically become visible within 3-14 days depending on the product selected, with peak effect occurring around 2-4 weeks. For patients planning treatment before a specific event, allowing 2-4 weeks for optimal results is generally recommended.
Effects are temporary, with typical duration ranging from 3-4 months for most products to 5-6 months for Daxxify in some patients. Maintenance treatments every few months are common for sustained results. Individual duration may vary, and some patients find they can extend intervals over time.
For cost considerations and budgeting guidance, review our treatment options. International patients may also find our travel coordination services guide helpful for planning.
Documentation matters for ongoing care
Request documentation of the specific product used, dosage, injection sites, and treatment date. This information supports continuity of care if switching providers or products and helps track your treatment history.
Disclose relevant medical information during consultation, including neuromuscular conditions, medications (particularly aminoglycosides, muscle relaxants, anticholinergics, and blood thinners), pregnancy status, and any allergies. This information helps providers assess treatment appropriateness and modify technique if needed.
Questions to Ask Your Provider
Preparing questions for consultation supports informed decision-making. Consider asking about:
Which specific product(s) the provider recommends for your treatment and why
The provider's experience with glabellar line injections specifically
Expected outcomes based on your individual assessment
Potential side effects and what to do if complications occur
Product documentation and tracking procedures
Aftercare instructions and follow-up protocols
Options if results do not meet expectations
Understanding these factors helps establish realistic expectations and supports a collaborative approach to treatment planning.
